Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001213900-26-059239
Filing Date
2026-05-20
Accepted
2026-05-20 07:24:53
Documents
10

Document Format Files

Seq Description Document Type Size
1 SOLICITING MATERIAL PURSUANT TO 240.14A-12 ea0291648-defa14a_vaxart.htm DEFA14A 26435
2 GRAPHIC ea029164801_img1.jpg GRAPHIC 1071101
3 GRAPHIC ea029164801_img2.jpg GRAPHIC 855924
4 GRAPHIC ea029164801_img3.jpg GRAPHIC 783461
5 GRAPHIC ea029164801_img4.jpg GRAPHIC 539428
6 GRAPHIC ea029164801_img5.jpg GRAPHIC 592864
7 GRAPHIC ea029164801_img6.jpg GRAPHIC 308512
8 GRAPHIC ea029164801_img7.jpg GRAPHIC 533821
9 GRAPHIC ea029164801_img8.jpg GRAPHIC 661506
10 GRAPHIC ea029164801_img9.jpg GRAPHIC 137580
  Complete submission text file 0001213900-26-059239.txt   7501406
Mailing Address 310 UTAH AVENUE, SUITE 150 SOUTH SAN FRANCISCO CA
Business Address 310 UTAH AVENUE, SUITE 150 SOUTH SAN FRANCISCO CA (650) 550-3500
Vaxart, Inc. (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35285 | Film No.: 261001395
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)